A Oneindia Venture
Click it and Unblock the Notifications
Emcure Pharmaceuticals Ltd. IPO
Emcure Pharmaceuticals Ltd., established in 1981, operates in the Pharmaceuticals sector. The company's IPO opened on July 3, 2024 and closed on July 5, 2024, with an issue price of ₹1008. The Emcure ... Read more
IPO Timeline
-
3 Jul 2024Bidding Starts
-
5 Jul 2024Bidding Ends
-
8 Jul 2024Allotment Finalization
-
10 Jul 2024Listing
About Emcure Pharmaceuticals Ltd.
We are an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. We are a research and development driven company with a differentiated product portfolio that includes orals, ... Read more
Emcure Pharmaceuticals Ltd. IPO Reservation
| Investors Category | Shares Offered |
|---|---|
| Anchor Investors | 57,76,934 (29.83%) |
| Employee Reserved | 1,08,900 (0.56%) |
| Non Institutional Investors | 28,88,467 (14.92%) |
| Qualified Institutional Buyers (QIBs) | 38,51,289 (19.89%) |
| Retail Individual Investors (RIIs) | 67,39,756 (34.8%) |
Emcure Pharmaceuticals Ltd. Financial Information
| Year End | Revenue | PAT | Reserves & Surplus |
|---|---|---|---|
| 31 Mar 2023 | 3,232.44 Cr | 166.21 Cr | 1,661.02 Cr |
| 31 Mar 2022 | 3,519.92 Cr | 446.81 Cr | 1,531.68 Cr |
| 31 Mar 2021 | 3,265.57 Cr | 438.76 Cr | 2,120.92 Cr |
Emcure Pharmaceuticals Ltd. Background
Our Company was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. Our Company ...
Read more-
1981Our Company was incorporated as Emcure Pharmaceuticals Private Limited
-
1999Amalgamation of Lasor Drugs Limited with our Company
-
2001Our Company was converted from a deemed public company into a public company
Amalgamation of Emcure Laboratories Private Limited, Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiralal Mehta Sales Private Limited with our Company.
Our Subsidiary, Gennova Biopharmaceuticals Limited was incorporated in India
-
2002Our Company received an approval to manufacture “S (-) Amlodipine Besilate tablets Asomex – 2.5” from the Joint Commissioner, Food and Drugs Administration, Pune, Maharashtra, India
Our Subsidiary, Zuventus Healthcare Limited, was incorporated in India
-
2006Blackstone GPV Capital Partners Mauritius V-C Ltd. subscribed to 226,325 Equity Shares of face value of ?10 each of our Company and 17,931,642 optionally convertible redeemable preference shares of our Company for the total investment of ?2,250 million.
Our Company established a facility at Kurkumbh, Pune, Maharashtra, India
Our Company commenced operations of injectables facility at Hinjawadi, Pune, Maharashtra, India
-
2007Facility established by our Subsidiary, Gennova at Hinjawadi, Pune, Maharashtra, India became operational
Our Subsidiary, Gennova received an approval from the Central Drugs Standard Control Organisation to start manufacturing “Recombinant Tissue Plasminogen Activator (TNK-t-PA)”
Our Subsidiary, Emcure Nigeria Limited, was incorporated in Nigeria
-
2009Our Company commenced production of tablets and capsules at our facility at Jammu, Jammu and Kashmir, India.
-
2010Our Subsidiary, Emcure Pharmaceuticals Mena FZ-LLC was incorporated in Dubai
Our Subsidiary, Emcure Pharmaceuticals South Africa (Pty) Ltd, was incorporated, in South Africa
-
2011Our Subsidiary, Emcure Brasil Farmaceutica LTDA, was incorporated, in Brazil
-
2012Our Company acquired rights of BICNU
Our Subsidiary, Emcure Pharma UK Ltd., was incorporated in the United Kingdom
-
2014BC Investments IV Limited acquired 13.09% of the then existing equity share capital of our Company (i.e., 5,918,386 Equity Shares of face value of ?10 each) from Blackstone GPV Capital Partners Mauritius V-C Ltd.
Our Subsidiary, Emcure UK acquired Tillomed Laboratories Limited
Our Subsidiary, Emcure Pharma Peru S.A.C., was incorporated in Peru
Our Subsidiary, Emcure Pharma Mexico S.A. DE C.V., was incorporated in Mexico
Our Subsidiary, Zuventus, obtained consent for establishment of industrial unit from Department of Commerce and Industries, Government of Sikkim, India
-
2015Our Company entered into Canada through acquisition of Marcan Pharmaceuticals Inc.
Our Subsidiary, Emcure Pharmaceuticals Pty Ltd., was incorporated in Australia
-
2016Tenecteplase (TNK – t – PA), manufactured by Gennova, approved for additional indication i.e., in thrombolytic treatment of the acute ischemic stroke within three hours of stroke initiation by the Directorate General of Health Services, CDSCO – Biological Division, Government of India
Our Subsidiary, Emcure UK acquired Bhardwaj Pharma GmbH (now known as Tillomed Pharma GmbH)
Our, Subsidiary Emcure UK acquired Laboratorios Tillomed Spain SLU
-
2017Our Subsidiary, Zuventus, established a manufacturing facility at Bengaluru, Karnataka, India
Our Subsidiary, Tillomed Italia S.R.L, was incorporated in Italy
-
2018Our Company received a license to work a factory in relation to the manufacturing facility situated at Sanand, Gujarat, India.
Our Subsidiary, Tillomed France S.A.S., was incorporated in France
-
2020Our Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile
-
2021Our Subsidiary, Lazor Pharmaceuticals Limited, was incorporated in Kenya
Our Subsidiary, Emcure Pharma Philippines Inc., was incorporated in Philippines
-
2022Our Subsidiary, Tillomed Malta Ltd, was incorporated in Malta
-
2023Our Subsidiary, Marcan Pharmaceuticals Inc., acquired Mantra Pharma Inc
1. Repayment and/or prepayment of all or a portion of certain outstanding borrowings availed by our Company
2. General corporate purposes
| Pricing Details | BSE | NSE |
|---|---|---|
| Issue Price | ₹ 1008.00 | ₹ 1008.00 |
| Open | ₹ 1325.05 | ₹ 1325.05 |
| Low | ₹ 1325.05 | ₹ 1325.05 |
| High | ₹ 1384.00 | ₹ 1385.00 |
| Last Trade | ₹ 1358.85 | ₹ 1359.15 |
1. Satish Ramanlal Mehta
2. Sunil Rajanikant Mehta
3. Namita Vikas Thapar
4. Samit Satish Mehta
The global pharmaceutical market is expected to sustain growth at a compound annual growth rate of approximately 5.0% to 5.5% between the calendar years 2023 and 2028, to reach approximately US$1,900 billion (approximately ?157 trillion) to US$1,950 billion (approximately ?161 trillion) in the ... Read more
FAQs
When does Emcure Pharmaceuticals Ltd. IPO opens and closes?
What is the size of Emcure Pharmaceuticals Ltd. IPO?
What is the price range of Emcure Pharmaceuticals Ltd. IPO?
What is the minimum investment and lot size required for the Emcure Pharmaceuticals Ltd. IPO?
When is Emcure Pharmaceuticals Ltd. IPO listing date?
What is the objective of Emcure Pharmaceuticals Ltd. IPO?
2. General corporate purposes
Latest Updates
Emcure Pharmaceuticals, the Pune-based pharmaceutical firm, made an impressive entry on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) today. The company's shares opened at Rs 1,325.05 per share, reflecting a 31.45% premium over the issue price of Rs 1,008 per share.
The initial public offering (IPO) of Emcure Pharmaceuticals was met with enthusiasm. According to data from the BSE, the IPO was oversubscribed 67.87 times. The response from non-institutional investors was particularly robust, with a subscription rate of 48.32 times. Retail investors also showed considerable interest, oversubscribing their portion by 7.21 times. The employee segment saw 8.81 times more subscriptions than available shares, and the qualified institutional buyers (QIB) category received bids 195.83 times the allotted shares.
The IPO, which closed on July 5, offered shares within a price band of Rs 960 to Rs 1,008. It included both a fresh issue of shares worth Rs 800 crore and an offer for sale (OFS) by existing promoters and shareholders amounting to Rs 1,151 crore. At the upper end of the pricing range, the total issue size was valued at Rs 1,952 crore.
10 July 2024Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article
-
CMPDI IPO Lists at 7% Discount on NSE, BSE; Weak Demand Keeps Stock Under Pressure Despite Mild Recovery -
CMPDI IPO Allotment Today: Did You Get Shares? Check Status Now on KFin, NSE, BSE -
Powerica IPO Off to Slow Start: GMP Up 1.2%, But Subscription Stuck at 0.01x; Is It Worth Applying? -
CMPDI IPO Underwhelms: Day 2 Subscription At 10%, No Movement In GMP; What's Behind The Weak Demand? -
Upcoming IPOs Next Week: CMPDI, Sai Parenteral, Powerica, Vivid Electromech, More | Check Full List -
XED Executive Development IPO: GIFT City Sees First IPO; Price Band, Issue Size | All You Need to Know -
Skyways Air IPO vs CMPDI IPO: Full Comparison of Price Band, GMP, Lot Size, Listing & Allotment Date -
Coal India's CMPDI IPO GMP Shows 11% Listing Gain Potential; Everything You Need To Know -
Big Change in IPO Rules: Govt Updates Minimum Public Offer Norms for for IPO-bound Firms -
Raajmarg Infra Investment Trust InvIT IPO Closed with 1323% Subscription on Day 3; GMP Remains Flat
-
Block for 8 hours
-
Block for 12 hours
-
Block for 24 hours
-
Don't block
Sign in with Google- Male
- Female
- Others
- Under 18
- 18 to 25
- 26 to 35
- 36 to 45
- 45 to 55
- 55+